AU2015292324A1

AU2015292324A1 - N-methyl-d-aspartate receptor modulators and methods of making and using same

N-methyl-d-aspartate receptor modulators and methods of making and using same Download PDF

Info

Publication number: AU2015292324A1
Authority: AU; Australia
Prior art keywords: group; independently selected; alkyl; ring atoms; phenyl
Prior art date: 2014-07-24
Legal status : Abandoned

Application number

AU2015292324A

Other languages

English (en)

Other versions

AU2015292324A8 (en

Inventor

M. Amin Khan

Current Assignee

Naurex Inc

Original Assignee

Naurex Inc

Priority date

2014-07-24

Filing date

2015-07-24

Publication date

2017-02-23

2015-07-24 Application filed by Naurex Inc filed Critical Naurex Inc

2017-02-23 Publication of AU2015292324A1 publication Critical patent/AU2015292324A1/en

2017-03-30 Publication of AU2015292324A8 publication Critical patent/AU2015292324A8/en

2021-02-16 Priority to AU2021201006A priority Critical patent/AU2021201006A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 47
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract description 30
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract description 30
150000001875 compounds Chemical class 0.000 claims abstract description 414
239000000203 mixture Substances 0.000 claims abstract description 55
229910052757 nitrogen Inorganic materials 0.000 claims description 324
125000006413 ring segment Chemical group 0.000 claims description 310
229910052736 halogen Inorganic materials 0.000 claims description 239
150000002367 halogens Chemical class 0.000 claims description 239
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 237
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 212
229910052739 hydrogen Inorganic materials 0.000 claims description 171
125000001424 substituent group Chemical group 0.000 claims description 171
239000001257 hydrogen Substances 0.000 claims description 170
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 159
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 143
125000001072 heteroaryl group Chemical group 0.000 claims description 141
125000000623 heterocyclic group Chemical group 0.000 claims description 138
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 110
125000000217 alkyl group Chemical group 0.000 claims description 95
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 92
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 73
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 73
229910052760 oxygen Inorganic materials 0.000 claims description 65
-1 cycloakyl Chemical group 0.000 claims description 63
229910052717 sulfur Inorganic materials 0.000 claims description 61
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 55
125000004043 oxo group Chemical group O=* 0.000 claims description 50
125000000000 cycloalkoxy group Chemical group 0.000 claims description 47
150000003839 salts Chemical class 0.000 claims description 34
125000004432 carbon atom Chemical group C* 0.000 claims description 28
125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 23
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
125000002252 acyl group Chemical group 0.000 claims description 17
125000004429 atom Chemical group 0.000 claims description 17
229910052799 carbon Inorganic materials 0.000 claims description 14
125000000753 cycloalkyl group Chemical group 0.000 claims description 14
125000005842 heteroatom Chemical group 0.000 claims description 14
206010015037 epilepsy Diseases 0.000 claims description 9
201000000980 schizophrenia Diseases 0.000 claims description 9
208000024827 Alzheimer disease Diseases 0.000 claims description 8
208000023105 Huntington disease Diseases 0.000 claims description 8
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
125000004423 acyloxy group Chemical group 0.000 claims description 7
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 6
GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims description 6
229910052702 rhenium Inorganic materials 0.000 claims description 6
208000010496 Heart Arrest Diseases 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
206010003805 Autism Diseases 0.000 claims description 4
208000020706 Autistic disease Diseases 0.000 claims description 4
208000001914 Fragile X syndrome Diseases 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 4
DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
208000020016 psychiatric disease Diseases 0.000 claims description 4
208000009999 tuberous sclerosis Diseases 0.000 claims description 4
208000030507 AIDS Diseases 0.000 claims description 3
208000000044 Amnesia Diseases 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 3
206010003591 Ataxia Diseases 0.000 claims description 3
206010008027 Cerebellar atrophy Diseases 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 3
206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
201000010374 Down Syndrome Diseases 0.000 claims description 3
208000010412 Glaucoma Diseases 0.000 claims description 3
208000030990 Impulse-control disease Diseases 0.000 claims description 3
208000001089 Multiple system atrophy Diseases 0.000 claims description 3
206010028570 Myelopathy Diseases 0.000 claims description 3
208000003435 Optic Neuritis Diseases 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
206010038923 Retinopathy Diseases 0.000 claims description 3
206010044688 Trisomy 21 Diseases 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
206010008129 cerebral palsy Diseases 0.000 claims description 3
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
230000000302 ischemic effect Effects 0.000 claims description 3
230000006984 memory degeneration Effects 0.000 claims description 3
208000023060 memory loss Diseases 0.000 claims description 3
229940127240 opiate Drugs 0.000 claims description 3
208000033808 peripheral neuropathy Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
208000020431 spinal cord injury Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
206010012335 Dependence Diseases 0.000 claims description 2
229960002715 nicotine Drugs 0.000 claims description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
238000009472 formulation Methods 0.000 abstract description 17
238000011282 treatment Methods 0.000 abstract description 16
230000000694 effects Effects 0.000 abstract description 5
230000013016 learning Effects 0.000 abstract description 4
208000004296 neuralgia Diseases 0.000 abstract description 4
208000021722 neuropathic pain Diseases 0.000 abstract description 4
230000036592 analgesia Effects 0.000 abstract description 2
238000001990 intravenous administration Methods 0.000 abstract description 2
230000001149 cognitive effect Effects 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 426
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 288
239000000243 solution Substances 0.000 description 166
239000011541 reaction mixture Substances 0.000 description 165
230000015572 biosynthetic process Effects 0.000 description 151
238000003786 synthesis reaction Methods 0.000 description 149
230000002829 reductive effect Effects 0.000 description 125
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 119
239000007858 starting material Substances 0.000 description 101
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 94
238000003756 stirring Methods 0.000 description 93
238000005481 NMR spectroscopy Methods 0.000 description 88
239000007787 solid Substances 0.000 description 82
239000012044 organic layer Substances 0.000 description 71
229910001868 water Inorganic materials 0.000 description 65
238000004440 column chromatography Methods 0.000 description 62
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
229940024606 amino acid Drugs 0.000 description 57
238000006243 chemical reaction Methods 0.000 description 57
239000012300 argon atmosphere Substances 0.000 description 49
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 40
229940125782 compound 2 Drugs 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 33
229940126214 compound 3 Drugs 0.000 description 33
229960002429 proline Drugs 0.000 description 33
QAMNALXDBDLRDT-QCJKKREZSA-N tert-butyl (1S,3S,5S)-3-[[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC([C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H]1N([C@H]2C[C@H]2C1)C(=O)OC(C)(C)C)=O)=O QAMNALXDBDLRDT-QCJKKREZSA-N 0.000 description 33
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 32
235000001014 amino acid Nutrition 0.000 description 31
150000001413 amino acids Chemical class 0.000 description 31
229940125904 compound 1 Drugs 0.000 description 31
229940125898 compound 5 Drugs 0.000 description 31
235000002639 sodium chloride Nutrition 0.000 description 31
239000007821 HATU Substances 0.000 description 30
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 30
WTZMHBNGUWJPRY-HDHGSYJOSA-N benzyl N-[(2S,3R)-1-[(3S)-3-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O WTZMHBNGUWJPRY-HDHGSYJOSA-N 0.000 description 30
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 28
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
239000012298 atmosphere Substances 0.000 description 25
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 23
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
150000001576 beta-amino acids Chemical group 0.000 description 23
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 22
239000012267 brine Substances 0.000 description 21
239000000706 filtrate Substances 0.000 description 21
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
238000004128 high performance liquid chromatography Methods 0.000 description 20
239000000470 constituent Substances 0.000 description 17
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
239000002904 solvent Substances 0.000 description 17
210000004899 c-terminal region Anatomy 0.000 description 16
FOTFFGRXJCVZPM-SYQHCUMBSA-N tert-butyl (3R)-3-[(3R)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O FOTFFGRXJCVZPM-SYQHCUMBSA-N 0.000 description 16
229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
235000017557 sodium bicarbonate Nutrition 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
238000004704 ultra performance liquid chromatography Methods 0.000 description 14
239000003039 volatile agent Substances 0.000 description 14
235000019439 ethyl acetate Nutrition 0.000 description 13
JSRABJUIBWRCCB-BBBLOLIVSA-N tert-butyl (3R)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O JSRABJUIBWRCCB-BBBLOLIVSA-N 0.000 description 13
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
GLHKTOYKVCKFAF-HKODNXKKSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O GLHKTOYKVCKFAF-HKODNXKKSA-N 0.000 description 12
125000003118 aryl group Chemical group 0.000 description 12
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 11
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 11
UVRXHGYFWZNYHF-AMOJAEELSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O UVRXHGYFWZNYHF-AMOJAEELSA-N 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
239000004471 Glycine Substances 0.000 description 10
230000027455 binding Effects 0.000 description 10
238000002953 preparative HPLC Methods 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
239000006188 syrup Substances 0.000 description 10
235000020357 syrup Nutrition 0.000 description 10
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
125000003545 alkoxy group Chemical group 0.000 description 9
125000000304 alkynyl group Chemical group 0.000 description 9
229930195712 glutamate Natural products 0.000 description 9
150000004677 hydrates Chemical class 0.000 description 9
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
239000002207 metabolite Substances 0.000 description 9
239000004031 partial agonist Substances 0.000 description 9
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
125000003342 alkenyl group Chemical group 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
239000012634 fragment Substances 0.000 description 8
239000012299 nitrogen atmosphere Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
WKDGOQQUSQDGEB-BMUNEFTBSA-N NC([C@H]([C@@H](C)O)NC([C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H]1N(C[C@@H](C1)OCC1=CC=CC=C1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC([C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H]1N(C[C@@H](C1)OCC1=CC=CC=C1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O)=O WKDGOQQUSQDGEB-BMUNEFTBSA-N 0.000 description 7
208000028017 Psychotic disease Diseases 0.000 description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
108091006146 Channels Proteins 0.000 description 6
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
125000003710 aryl alkyl group Chemical group 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
125000001188 haloalkyl group Chemical group 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
125000001931 aliphatic group Chemical group 0.000 description 5
239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
125000004122 cyclic group Chemical group 0.000 description 5
239000003446 ligand Substances 0.000 description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
239000000047 product Substances 0.000 description 5
150000003254 radicals Chemical class 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
206010012239 Delusion Diseases 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
239000000556 agonist Substances 0.000 description 4
125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
125000004448 alkyl carbonyl group Chemical group 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 4
231100000868 delusion Toxicity 0.000 description 4
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000027928 long-term synaptic potentiation Effects 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
150000002894 organic compounds Chemical class 0.000 description 4
208000002851 paranoid schizophrenia Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
AKCMCFPQVUTWFW-UHFFFAOYSA-N pyrrolidin-3-yl acetate Chemical compound CC(=O)OC1CCNC1 AKCMCFPQVUTWFW-UHFFFAOYSA-N 0.000 description 4
IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
231100001274 therapeutic index Toxicity 0.000 description 4
GIBQQARAXHVEGD-KJKVDNPUSA-N (2R)-1-[(2R)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound N[C@@H]([C@H](O)C)C(=O)N1[C@@H](C(=O)N2[C@H](CCC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 GIBQQARAXHVEGD-KJKVDNPUSA-N 0.000 description 3
GNJJDPCXOAHTSB-BSOLPCOYSA-N (2S)-1-[(3S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-3-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound N[C@@H]([C@H](O)C)C(=O)N1C[C@H](CC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C(=O)N)[C@@H](C)O GNJJDPCXOAHTSB-BSOLPCOYSA-N 0.000 description 3
LLHOYOCAAURYRL-RITPCOANSA-N (2s,3r)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)OC(C)(C)C LLHOYOCAAURYRL-RITPCOANSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
208000020925 Bipolar disease Diseases 0.000 description 3
201000006474 Brain Ischemia Diseases 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
208000036753 Schizophrenia, disorganised type Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
125000002015 acyclic group Chemical group 0.000 description 3
125000005133 alkynyloxy group Chemical group 0.000 description 3
230000003281 allosteric effect Effects 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WTZMHBNGUWJPRY-YBZCJVABSA-N benzyl N-[(2S,3R)-1-[(3R)-3-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O WTZMHBNGUWJPRY-YBZCJVABSA-N 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003480 eluent Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
230000000971 hippocampal effect Effects 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
238000011457 non-pharmacological treatment Methods 0.000 description 3
238000011458 pharmacological treatment Methods 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
230000001242 postsynaptic effect Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
125000000719 pyrrolidinyl group Chemical group 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
238000001665 trituration Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
JFMBOYSYTBNVQK-DBIOUOCHSA-N (2R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2R)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound N1[C@@H](C(=O)N2[C@H](CCC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 JFMBOYSYTBNVQK-DBIOUOCHSA-N 0.000 description 2
JFMBOYSYTBNVQK-YTWAJWBKSA-N (2R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound N1[C@H](C(=O)N2[C@H](CCC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 JFMBOYSYTBNVQK-YTWAJWBKSA-N 0.000 description 2
WYSGOIPWIUKOOD-YTWAJWBKSA-N (2R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(3S)-pyrrolidine-3-carbonyl]pyrrolidine-2-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1CNCC1)=O WYSGOIPWIUKOOD-YTWAJWBKSA-N 0.000 description 2
JFMBOYSYTBNVQK-ZNSHCXBVSA-N (2S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2R)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound N1[C@@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 JFMBOYSYTBNVQK-ZNSHCXBVSA-N 0.000 description 2
WYSGOIPWIUKOOD-ZNSHCXBVSA-N (2S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(3R)-pyrrolidine-3-carbonyl]pyrrolidine-2-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1CNCC1)=O WYSGOIPWIUKOOD-ZNSHCXBVSA-N 0.000 description 2
WYSGOIPWIUKOOD-RCWTZXSCSA-N (2S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(3S)-pyrrolidine-3-carbonyl]pyrrolidine-2-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CNCC1)=O WYSGOIPWIUKOOD-RCWTZXSCSA-N 0.000 description 2
GIBQQARAXHVEGD-PRFQISJJSA-N (2s)-1-[(2r)-1-[(2s,3r)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-PRFQISJJSA-N 0.000 description 2
ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
IPJUIRDNBFZGQN-SCZZXKLOSA-N (2s,3r)-3-hydroxy-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 IPJUIRDNBFZGQN-SCZZXKLOSA-N 0.000 description 2
HKDXLNSBJRRLGB-DBIOUOCHSA-N (3R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2R)-pyrrolidine-2-carbonyl]pyrrolidine-3-carboxamide Chemical compound N1[C@@H](C(=O)N2C[C@@H](CC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 HKDXLNSBJRRLGB-DBIOUOCHSA-N 0.000 description 2
HKDXLNSBJRRLGB-ZNSHCXBVSA-N (3R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-3-carboxamide Chemical compound N1[C@H](C(=O)N2C[C@@H](CC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 HKDXLNSBJRRLGB-ZNSHCXBVSA-N 0.000 description 2
CJLLWRDXDCDASJ-DBIOUOCHSA-N (3R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(3R)-pyrrolidine-3-carbonyl]pyrrolidine-3-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CNCC1)=O CJLLWRDXDCDASJ-DBIOUOCHSA-N 0.000 description 2
HKDXLNSBJRRLGB-YTWAJWBKSA-N (3S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2R)-pyrrolidine-2-carbonyl]pyrrolidine-3-carboxamide Chemical compound N1[C@@H](C(=O)N2C[C@H](CC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 HKDXLNSBJRRLGB-YTWAJWBKSA-N 0.000 description 2
HKDXLNSBJRRLGB-RCWTZXSCSA-N (3S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-3-carboxamide Chemical compound N1[C@H](C(=O)N2C[C@H](CC2)C(=O)N[C@H](C(=O)N)[C@@H](C)O)CCC1 HKDXLNSBJRRLGB-RCWTZXSCSA-N 0.000 description 2
GSHIEKFUNNQYRA-VQVTYTSYSA-N (3S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-3-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CNCC1)=O GSHIEKFUNNQYRA-VQVTYTSYSA-N 0.000 description 2
HRMRQBJUFWFQLX-SSDOTTSWSA-N (3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](C(O)=O)C1 HRMRQBJUFWFQLX-SSDOTTSWSA-N 0.000 description 2
HRMRQBJUFWFQLX-ZETCQYMHSA-N (3s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C(O)=O)C1 HRMRQBJUFWFQLX-ZETCQYMHSA-N 0.000 description 2
125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 2
125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108091005462 Cation channels Proteins 0.000 description 2
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
229930182820 D-proline Natural products 0.000 description 2
208000024254 Delusional disease Diseases 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 2
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 2
208000036572 Myoclonic epilepsy Diseases 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000036755 Schizophrenia simple Diseases 0.000 description 2
208000036754 Schizophrenia, catatonic type Diseases 0.000 description 2
208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
UOFKNJHGULDIFQ-BNOWGMLFSA-N benzyl (2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O UOFKNJHGULDIFQ-BNOWGMLFSA-N 0.000 description 2
UOFKNJHGULDIFQ-XBFCOCLRSA-N benzyl (2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O UOFKNJHGULDIFQ-XBFCOCLRSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
206010007776 catatonia Diseases 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
239000013058 crude material Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
230000002461 excitatory amino acid Effects 0.000 description 2
239000003257 excitatory amino acid Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
125000004446 heteroarylalkyl group Chemical group 0.000 description 2
125000005844 heterocyclyloxy group Chemical group 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
201000003723 learning disability Diseases 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
208000024714 major depressive disease Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000015654 memory Effects 0.000 description 2
HQEIPVHJHZTMDP-NUBCRITNSA-N methyl (2r)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@H]1CCCN1 HQEIPVHJHZTMDP-NUBCRITNSA-N 0.000 description 2
239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
230000036407 pain Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000005897 peptide coupling reaction Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
210000001176 projection neuron Anatomy 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 2
VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 2
201000005070 reflex epilepsy Diseases 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
208000012672 seasonal affective disease Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
230000035882 stress Effects 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
JSRABJUIBWRCCB-UTLUCORTSA-N tert-butyl (3S)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O JSRABJUIBWRCCB-UTLUCORTSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
VXIIZQXOIDYWBS-FXQIFTODSA-N (1s,3s,5s)-2-[(2-methylpropan-2-yl)oxycarbonyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)[C@H]2C[C@H]21 VXIIZQXOIDYWBS-FXQIFTODSA-N 0.000 description 1
JSJGGZCLYZACPF-VQVTYTSYSA-N (2S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1NCCC1)=O JSJGGZCLYZACPF-VQVTYTSYSA-N 0.000 description 1
DGIGGVANZFKXLS-KGLIPLIRSA-N (2s,4r)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxypyrrolidine-2-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C[C@@H]1OCC1=CC=CC=C1 DGIGGVANZFKXLS-KGLIPLIRSA-N 0.000 description 1
NEGUECGQWNOKOA-BDAKNGLRSA-N (2s,4r)-4-acetyloxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C1 NEGUECGQWNOKOA-BDAKNGLRSA-N 0.000 description 1
BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
COHIMMPWCAHSFN-SFYZADRCSA-N (2s,4r)-4-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CO[C@@H]1C[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C1 COHIMMPWCAHSFN-SFYZADRCSA-N 0.000 description 1
GSHIEKFUNNQYRA-QYNIQEEDSA-N (3R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-3-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CNCC1)=O GSHIEKFUNNQYRA-QYNIQEEDSA-N 0.000 description 1
UQGICJKOVMNOFQ-BDSKVXAXSA-N (3S,3aS,6aR)-N-[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole-3-carboxamide Chemical compound NC([C@H]([C@@H](C)O)NC([C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H]1NC[C@H]2[C@@H]1CCC2)=O)=O UQGICJKOVMNOFQ-BDSKVXAXSA-N 0.000 description 1
SFBZDQKMJLUZQF-GUBZILKMSA-N (3s,3as,6ar)-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-3-carboxylic acid Chemical compound C1CC[C@@H]2[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)C[C@@H]21 SFBZDQKMJLUZQF-GUBZILKMSA-N 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
UJOYFRCOTPUKAK-MRVPVSSYSA-N (R)-3-ammonio-3-phenylpropanoate Chemical compound OC(=O)C[C@@H](N)C1=CC=CC=C1 UJOYFRCOTPUKAK-MRVPVSSYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
208000021465 Brief psychotic disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
208000001495 Disorganized Schizophrenia Diseases 0.000 description 1
201000007547 Dravet syndrome Diseases 0.000 description 1
206010016759 Flat affect Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
201000009010 Frontal lobe epilepsy Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019070 Hallucination, auditory Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010021750 Infantile Spasms Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000005870 Lafora disease Diseases 0.000 description 1
208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
208000020358 Learning disease Diseases 0.000 description 1
201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
208000002033 Myoclonus Diseases 0.000 description 1
NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 description 1
QLAABSQFPROPPD-RDSXUSOHSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CN(CC1)C(=O)[C@@H]1N(CCC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CN(CC1)C(=O)[C@@H]1N(CCC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O QLAABSQFPROPPD-RDSXUSOHSA-N 0.000 description 1
GLHKTOYKVCKFAF-RDSXUSOHSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O GLHKTOYKVCKFAF-RDSXUSOHSA-N 0.000 description 1
GLHKTOYKVCKFAF-AMOJAEELSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O GLHKTOYKVCKFAF-AMOJAEELSA-N 0.000 description 1
WMHRUUDQAWBTIS-VTLVALNESA-N NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O WMHRUUDQAWBTIS-VTLVALNESA-N 0.000 description 1
SKDQORLJPGHTGT-YBZCJVABSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1N(CCC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1N(CCC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O SKDQORLJPGHTGT-YBZCJVABSA-N 0.000 description 1
GLHKTOYKVCKFAF-KAGOGRAWSA-N NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O[Si](C)(C)C(C)(C)C)NC(OCC1=CC=CC=C1)=O)=O)=O GLHKTOYKVCKFAF-KAGOGRAWSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000037158 Partial Epilepsies Diseases 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
201000009916 Postpartum depression Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000036750 Schizophrenia, residual type Diseases 0.000 description 1
208000024791 Schizotypal Personality disease Diseases 0.000 description 1
206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
208000019568 Shared Paranoid disease Diseases 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
231100000643 Substance intoxication Toxicity 0.000 description 1
208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
201000006791 West syndrome Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
RMQXUAYCXLDUKS-WCCKRBBISA-N [N].OC(=O)[C@@H]1CCCN1 Chemical group [N].OC(=O)[C@@H]1CCCN1 RMQXUAYCXLDUKS-WCCKRBBISA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003302 alkenyloxy group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000008856 allosteric binding Effects 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000008503 anti depressant like effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
208000022804 avoidant personality disease Diseases 0.000 description 1
MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
MEPJLBXTZZGXOV-UHFFFAOYSA-N azidocarbamic acid Chemical compound OC(=O)NN=[N+]=[N-] MEPJLBXTZZGXOV-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
NNESSDSWSGIFDL-SPUZQDLCSA-N benzyl (2R)-2-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O NNESSDSWSGIFDL-SPUZQDLCSA-N 0.000 description 1
ZOIJSZDOXNPZDM-DDBAPUKQSA-N benzyl (2R)-2-[(3R)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O ZOIJSZDOXNPZDM-DDBAPUKQSA-N 0.000 description 1
ZOIJSZDOXNPZDM-SPUZQDLCSA-N benzyl (2R)-2-[(3S)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CN(CC1)C(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O ZOIJSZDOXNPZDM-SPUZQDLCSA-N 0.000 description 1
NNESSDSWSGIFDL-BGTYHANMSA-N benzyl (2S)-2-[(2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O NNESSDSWSGIFDL-BGTYHANMSA-N 0.000 description 1
ZOIJSZDOXNPZDM-BGTYHANMSA-N benzyl (2S)-2-[(3R)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O ZOIJSZDOXNPZDM-BGTYHANMSA-N 0.000 description 1
ZOIJSZDOXNPZDM-UBDQQSCGSA-N benzyl (2S)-2-[(3S)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1CN(CC1)C(=O)[C@H]1N(CCC1)C(=O)OCC1=CC=CC=C1)=O ZOIJSZDOXNPZDM-UBDQQSCGSA-N 0.000 description 1
YIPAWZBMJCLRFH-SWYLZYKNSA-N benzyl N-[(2S,3R)-1-[(2R)-2-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1N(CCC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O YIPAWZBMJCLRFH-SWYLZYKNSA-N 0.000 description 1
WTZMHBNGUWJPRY-VTLVALNESA-N benzyl N-[(2S,3R)-1-[(3R)-3-[(2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O WTZMHBNGUWJPRY-VTLVALNESA-N 0.000 description 1
WTZMHBNGUWJPRY-SWYLZYKNSA-N benzyl N-[(2S,3R)-1-[(3S)-3-[(2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]carbamate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C([C@H]([C@@H](C)O)NC(OCC1=CC=CC=C1)=O)=O)=O WTZMHBNGUWJPRY-SWYLZYKNSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
208000022257 bipolar II disease Diseases 0.000 description 1
208000030963 borderline personality disease Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000005518 carboxamido group Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
230000006726 chronic neurodegeneration Effects 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000007422 cognition related pathway Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
150000001924 cycloalkanes Chemical class 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
208000026725 cyclothymic disease Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000003492 excitotoxic effect Effects 0.000 description 1
231100000063 excitotoxicity Toxicity 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000011737 fluorine Chemical group 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004405 heteroalkoxy group Chemical group 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
125000005368 heteroarylthio group Chemical group 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000005980 hexynyl group Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000010365 information processing Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
KALWJAOLQCJRJQ-HZPDHXFCSA-N methyl (2R)-1-[(2R)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1 KALWJAOLQCJRJQ-HZPDHXFCSA-N 0.000 description 1
KALWJAOLQCJRJQ-CVEARBPZSA-N methyl (2S)-1-[(2R)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1N(CCC1)C(=O)OCC1=CC=CC=C1 KALWJAOLQCJRJQ-CVEARBPZSA-N 0.000 description 1
KALWJAOLQCJRJQ-JKSUJKDBSA-N methyl (2r)-1-[(2s)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@H]1CCCN1C(=O)[C@H]1N(C(=O)OCC=2C=CC=CC=2)CCC1 KALWJAOLQCJRJQ-JKSUJKDBSA-N 0.000 description 1
BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
ZORHSASAYVIBLY-UHNVWZDZSA-N methyl (2s,4r)-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1 ZORHSASAYVIBLY-UHNVWZDZSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000007383 nerve stimulation Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
LBOJYSIDWZQNJS-UHFFFAOYSA-N neurogard Chemical compound C12=CC=CC=C2C2(C)C3=CC=CC=C3CC1N2 LBOJYSIDWZQNJS-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005475 oxolanyl group Chemical group 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Chemical group 0.000 description 1
201000003040 photosensitive epilepsy Diseases 0.000 description 1
125000005544 phthalimido group Chemical group 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
TURAMGVWNUTQKH-UHFFFAOYSA-N propa-1,2-dien-1-one Chemical group C=C=C=O TURAMGVWNUTQKH-UHFFFAOYSA-N 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
208000005809 status epilepticus Diseases 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000008053 sultones Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000003956 synaptic plasticity Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
201000008914 temporal lobe epilepsy Diseases 0.000 description 1
ZWGJNAKACNUHBP-NPZIIBKFSA-N tert-butyl (2S,4R)-4-acetyloxy-2-[[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](C[C@H](C1)OC(C)=O)C(N[C@H](C(=O)N[C@H](C(=O)N)[C@@H](C)O)CC1=CNC2=CC=CC=C12)=O ZWGJNAKACNUHBP-NPZIIBKFSA-N 0.000 description 1
ZTSYWEUVZANLFQ-SYQHCUMBSA-N tert-butyl (3R)-3-[(2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O ZTSYWEUVZANLFQ-SYQHCUMBSA-N 0.000 description 1
ZTSYWEUVZANLFQ-MQYQWHSLSA-N tert-butyl (3R)-3-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O ZTSYWEUVZANLFQ-MQYQWHSLSA-N 0.000 description 1
ZTSYWEUVZANLFQ-RQJABVFESA-N tert-butyl (3S)-3-[(2R)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O ZTSYWEUVZANLFQ-RQJABVFESA-N 0.000 description 1
ZTSYWEUVZANLFQ-RFGFWPKPSA-N tert-butyl (3S)-3-[(2S)-2-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O ZTSYWEUVZANLFQ-RFGFWPKPSA-N 0.000 description 1
FOTFFGRXJCVZPM-MQYQWHSLSA-N tert-butyl (3S)-3-[(3R)-3-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound NC([C@H]([C@@H](C)O)NC(=O)[C@H]1CN(CC1)C(=O)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O FOTFFGRXJCVZPM-MQYQWHSLSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
125000001166 thiolanyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000011491 transcranial magnetic stimulation Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
239000003174 triple reuptake inhibitor Substances 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000031836 visual learning Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1